Cancer development involves major alterations in cells' metabolism. Enhanced glycolysis and de novo fatty acids synthesis are indeed characteristic features of cancer. Cell proliferation and metabolism are tightly linked cellular processes. Others and we have previously shown a close relationship between metabolic responses and proliferative stimuli. In addition to trigger proliferative and survival signaling pathways, most oncoproteins also trigger metabolic changes to transform the cell. We present herein the view that participation of cell-cycle regulators and oncogenic proteins to cancer development extend beyond the control of cell proliferation, and discuss how these new functions may be implicated in metabolic alterations concomitant to the pathogenesis of human cancers.
Introduction
Over the past decades, accumulating evidence of a metabolic reorganization during cancer development has emerged from studies on various tumor types. We present herein the view that participation of cell-cycle regulators and oncogenic proteins in cancer development extend beyond the control of cell proliferation, and discuss how these new functions may be implicated in metabolic alterations concomitant to the pathogenesis of human cancers. This is consistent with the observation that changes in metabolism are part of a coordinated response of the cell to distinct physiological and pathological conditions. In mammalian cells the metabolic response requires a permanent coordination of cell activity, including cell proliferation with nutrient availability, hormonal and stress signaling and with regulation of energy homeostasis. This links external signaling events with the activation or inhibition of particular metabolic pathways, such as oxidative or glycolytic metabolism, and biosynthetic processes. Nutrient availability enables nucleic acids, proteins and lipids synthesis to promote cell growth and proliferation. It is also correlated with increased glycolytic flux, and decreased oxidative metabolism (Jezek et al., 2010) . Conversely, nutrient deprivation implicates a metabolic switch that triggers energy production pathways, such as oxidative phosphorylation that restrict cell proliferation. In general, cell proliferation and metabolism are tightly linked cellular processes. In nonproliferating cells from differentiated tissues, catabolic metabolism is predominantly used to fuel energetic needs, and is associated to preferential use of mitochondrial oxidative phosphorylation (OXPHOS) with oxidation of macromolecules. In sharp contrast, in tissues with high proliferative rate, bioenergetics resources and biosynthetic pathways are reorganized to allow cell-cycle progression, leading to a shift toward an anabolic metabolism, with high glycolytic flux, lactate production and biosynthesis of macromolecules. Several physiopathological conditions are indeed characterized by a switch from an oxidative to a glycolytic metabolism. This is the case for developmental processes, tissue regeneration, intensive exercise or immune response. In a pathological context, it is currently well established that cancer growth and invasion also involve major alterations in cells' metabolism. Therefore, a common regulatory pathway exists between cell proliferation and metabolism to insure a coordinated cellular response. This supports the hypothesis, which we develop in this review, that the same factors that trigger proliferation, such as oncogenes or cell-cycle regulators, are indeed coordinators of the metabolic response of the cells to the external stimuli.
Metabolic changes in cancer: the contribution of lipids metabolism
One of the first identified biochemical hallmarks of cancer cells was change in metabolism. Early in the last century, Warburg (1930) observed that tumor cells have a higher rate of glucose metabolism than their normal counterparts and preferentially use glycolysis instead of OXPHOS even under appropriate oxygen concentrations (Warburg, 1930 (Warburg, , 1956a (Warburg, , 1956b . Since this first observation, the 'aerobic' glycolysis switch has been detected in many tumor types and cumulating studies on various proliferating cells have led to the evidence of a global metabolic reorganization concomitant to cancer progression. Most tumor cells are characterized by higher rates of glycolysis, lactate production, and macromolecules and lipids biosynthesis (Kroemer and Pouyssegur, 2008; Vander Heiden et al., 2009) . During aerobic glycolysis, glucose is converted to pyruvate, and the final subproduct of this reaction is lactate, which is exported out of the cell, contributing to extracellular acidification. The preferential use of aerobic glycolysis offers several advantages to highly proliferating cells, concerning both bioenergetics and biosynthetic requirements. First, it allows for the use of the most abundant extracellular nutrient, which is glucose.
Second, the flux of ATP can exceed that produced during OXPHOS. Third, it is likely that one of the critical roles of aerobic glycolysis in cancer cells is to provide essential metabolic intermediates for biosynthesis of macromolecules (lipids, proteins and nucleic acids) to support increased proliferation .
Increased de novo fatty acid (FA) synthesis, or lipogenesis, is considered as another major metabolic alteration of cancer cells (Medes et al., 1953; Sabine et al., 1967) . Figure 1 summarizes 
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Glycogen synthesis Figure 1 Cross talk between glycolysis and de novo FA synthesis in cancer cells. This model highlights the main differences in glucose and fatty acids use between quiescent (a) and highly proliferative cells (b). Red arrows indicate preferred metabolic pathway. In nonproliferating cells glucose can either be used for glycogen or fatty acids synthesis, or can be converted to pyruvate through basal rate of glycolysis that occurs in the cytoplasm. Pyruvate is then imported into the mitochondrion where it is decarboxylated to acetyl Coa or oxaloacetate (OAA). Circulating fatty acids are also imported into nonproliferating cells where they are stored as triglycerides or oxidized into the mitochondrion to generate acetyl-CoA. Acetyl-CoA derived from both glucose and fatty acids is then oxidized through TCA cycle that produces intermediate citrate that is directed toward mitochondrial OXPHOS to generate ATP. In contrast, in proliferative cancer cells, the glycolytic flux is largely increased and most of the imported glucose is converted to the glycolytic end product, pyruvate. The resulting pyruvate is mainly converted to lactate which is secreted from the cells, whereas the remaining pyruvate is converted to acetyl-CoA, which in turn is directed toward de novo FA synthesis. Circulating fatty acids are also mainly oxidized to generate acetyl-CoA. Acetyl-CoA derived from both glucose and fatty acids is then oxidized through TCA cycle to produced intermediate citrate. The resulting citrate is not directed toward OXPHOS but rather is exported to the cytoplasm where it is reconverted to acetyl-CoA, which, in turn, is used for de novo fatty acids biosynthesis. Glc, glucose; FA, fatty acids; OAA, oxaloacetate; TCA, tricarboxylic acid; OXPHOS, oxidative phosphorylation. (Medes et al., 1953) . The increased lipogenesis in cancer is reflected in overexpression and hyperactivity of lipogenic enzymes such as ATP citrate lyase (ACL), acetyl-CoA carboxylase (ACC) or the fatty acid synthase (FAS) (Kuhajda, 2000) . ACC carboxylates acetyl-CoA to form malonyl-CoA, which is further converted to long-chain FA by FAS. Interestingly, studies with chemical inhibitors have revealed that inhibition of FAS activity results in decreased proliferation and increased apoptosis of cancer cells (Kuhajda et al., 1994; Kuhajda, 2000) . De novo FA biosynthesis is required for cancer cells to synthesize new membranes, which have a particular lipidic composition that facilitates the formation of lipid rafts for increased signaling of cell growth receptors. Some lipid synthesis intermediates, such as malonyl-CoA, participate in the transcriptional regulation of growth factor receptors (reviewed in Menendez and Lupu, 2007) . Moreover, circulating lipids impact on cell cancer growth, migration and invasion. This is the case for the lysophosphatidic acid, which signals through lysophosphatidic acid receptors to stimulate cancer cell proliferation and survival . Enhanced lipogenesis in cancer cells has also been proposed to be required to balance the redox potential through the use of nicotinamide adenine dinucleotide phosphate oxidase (Porstmann et al., 2009 ). In addition, de novo FA synthesis in cancer cells facilitates the production of lipids that will regulate the activity of various oncogenes. Indeed, signaling lipids, such as phosphatidylinositol, phosphatidyl serine or phosphatidyl choline, are recognized to be important factors that activate and mediate proliferative and survival pathways, notably the PI3K/AKT, Ras or Wnt pathways (Nadolski and Linder, 2007) . Finally, post-translational modification with lipid moieties is also a key process regulating transport and function of various cellular and secreted oncoproteins. Indeed, several studies have shown that FA synthesis facilitates the formation of particular FA that modify the protein structure of a particular set of oncogenes, such as Ras, Src, Wnt. This in turn facilitates the activation of their oncogenic pathways (Xue et al., 2004; Nadolski and Linder, 2007) . These findings highlight the relevance of lipid synthesis in oncogenesis and fully support the investigation of lipid synthesis inhibitors as anticancer agents.
Cell cycle, transcription factors and oncogenes as dual proliferation-metabolism regulators
Increasing evidence support the symmetrical effects of oncogenes and cell-cycle regulators on metabolic pathways. Uncontrolled cell growth is an invariable characteristic of human cancer that implies well-documented genetic alterations of the cell-cycle regulators, particular transcription factors and oncogenes. Importantly, beside their well-known role in controlling cell proliferation, increasing evidence points to these factors as crucial regulators of cell metabolism. It is likely that oncogenic and proliferative factors not only control proliferation and spread of cancer cells, but also concomitantly trigger an adapted metabolic response of these cells. This is illustrated in Figure 2 , and is discussed below.
Cell-cycle regulators
Cell-cycle progression is a tightly regulated process that supports cell proliferation during normal growth and development. It involves the coordinated action of many regulatory proteins that comprise the retinoblastoma tumor suppressor family (pRB, p107, p130), the cyclindependent kinases (cdks) and their regulatory partners the cyclins (cyc), as well as the family of the cdk inhibitors. Members of E2F transcription factors (E2F1-8) family have pivotal role in regulating survival and proliferation, by exerting cell-cycle-specific expression to promoters containing E2F-binding sites, which concern many genes involved in cell-cycle progression (Helin, 1998) . Indeed, E2F activity is essential for transactivation of genes that regulate the onset of S phase, such as c-Myc and cyclin E, DNA replication and mitosis. When they do not function as free heterodimers with DP1 or DP2, E2Fs exist in repressive association with members of the pRB family that actively inhibit E2F transactivation through the recruitment of histones deacetylases (Brehm et al., 1998; Magnaghi-Jaulin et al., 1998) and lysine/arginine methyltransferases (Fabbrizio et al., 2002) . The subsequent phosphorylation of retinoblastoma proteins by the cyclin-cdk complexes releases E2Fs, allowing transcription of their target genes and cell-cycle progression trough the G 1 /S phase (Dimova and Dyson, 2005) . E2F activity is commonly increased in numerous human cancers, including glioblastoma, lung, ovarian, breast, stomach and colon cancers (Chen et al., 2009) , and much evidence supports an oncogenic role for E2F1-3. It is clear that the increased expression of E2Fs contributes to the uncontrolled proliferation of cancer cells, although a specific role of E2Fs in the deregulation of cancer cell metabolism cannot be ruled out. There is compelling evidence for an E2F-RB-specific effect in metabolism. This includes a recent observation implicating RB in the control of oxidative metabolism in adipose tissue (DaliYoucef et al., 2007) . In addition, we previously showed that cell-cycle regulators participate in lipids metabolism. We showed that E2Fs regulate adipogenesis through modulating the expression of the nuclear receptor PPARg, which is a master regulator of adipogenesis (Fajas et al., 2002b) . Similarly, we have documented the adipogenic role of cyclin D3 (Sarruf et al., 2005) , cdk4 and cdk9 (Iankova et al., 2006) through their positive regulation of PPARg activity. At the opposite, we found that PPARg activity and adipocyte differentiation are repressed by RB through the recruitment of HDAC3 (Fajas et al., 2002a) .
Although no gross abnormalities were originally observed in E2F1À/À mice (Field et al., 1996; Yamasaki et al., 1996) , a first evidence for a role of E2F1 in regulating glucose homeostasis came from the observation that E2F1À/À mice present impaired postnatal pancreatic growth and dysfunctional b-cells associated with defective insulin secretion and glucose intolerance (Fajas et al., 2004) . Furthermore, the observation that E2F1 was robustly expressed in nonproliferating b-cells suggested a role for E2F1 in pancreatic b-cells, independent to the control of proliferation. This hypothesis was demonstrated showing that the CDK4-pRB-E2F1 pathway mediates the transcriptional response to glucose regulating the expression of genes such as Kir6.2, a key component of the K ATP channel involved in the regulation of glucose-induced insulin secretion (Annicotte et al., 2009) . This role of E2F1 seems to be specific of this E2F family member, as no major metabolic phenotype has been observed in other E2FÀ/À mice. E2F2 could however partially compensate E2F1 deficiency. Indeed E2F1-2À/À mice are diabetic, but contribution of E2F2 is likely related to its role in bone-marrow-derived cells (Li et al., 2003; Iglesias et al., 2004) . Recent data suggest, in addition, that E2F1 is involved in the control of several other metabolic processes. In a genome-wide study approach, a cohort of genes that are involved in mitochondrial function were identified among E2F targets, indicating a potential role for E2Fs in linking the metabolic state of the cell to cell-cycle status (Cam et al., 2004) . E2F1 transcriptional activation of the pyruvate dehydrogenase kinase 4 (PDK4) gene, a key nutrient sensor that is constitutively highly expressed in diabetes, was also shown to regulate glucose homeostasis in muscle through inhibition of glucose oxidation (Hsieh et al., 2008) . More recently, we also evidenced that E2F1 is a negative regulator of oxidative metabolism in skeletal muscle through the repression of PGC-1-a (unpublished results), suggesting that E2F1 may participate in the metabolic switch from OXPHOS to aerobic glycolysis in proliferative cells. Taken together, these results support a dual role for the E2F pathway in the control of both cell proliferation and the metabolic response (Figure 3 ).
Sp family of transcription factors
Members of the Sp/KLF family of transcription factors, Sp1, Sp3 and Sp4, which are overexpressed in a variety of cancers are known to regulate cell proliferation by modulating the expression of genes containing GC-rich Sp1-binding sites, including, but not limited to, several cell-cycle regulatory proteins (Black et al., 2001) . Interestingly, Sp1 sites were also found in the promoters of lipogenic enzymes, such as ACL, ACC and FAS (Daniel and Kim 1996; Moon et al., 1999; Xiong et al., 2000) and it was previously showed that both Sp1 and Sp3 can activate ACL in response to glucose in Figure 2 Oncogenic regulatory pathways in the control of the cancer cells metabolism. This scheme represents the main implications of oncogenic pathways (in red) in the regulation of glycolysis and de novo lipogenesis in cancer cells. Metabolic effects of the PI3K/Akt, Ras and c-Myc oncogenic pathways include enhanced glucose uptake through increased surface expression of glucose transporter. Hence, they enhance the glycolytic flux, including lactate production, by stimulating glycolytic enzymes activity. Moreover, both Akt and Ras signaling promote de novo FA synthesis through increased SREBP-1-mediated transcription of lipogenic enzymes, and direct stimulation of ACL activity by Akt channels glucose-derived metabolites toward de novo FA biosynthesis. In cooperation with E2F1, c-Myc promotes the transcription of enzymes necessary to support nucleotides biosynthesis from intermediates of the glycolysis. In the case of p53 or PTEN tumor suppressors (in blue), loss-of-function mutations in cancer cells have the opposite of the effects shown here. Glc, glucose; HK, hexokinase; Glc-6-P, glucose-6-phosphate; 3-PG, 3-phosphoglycerate; GF, growth factors; PI3K, phosphatidylinositol 3-kinase; PIP 3 , phosphatidylinositol triphosphate; PTEN, phosphatase and tensin homologue; MAPK, mitogenactivated protein kinase; SREBP, sterol-regulatory element-binding protein; LDH-A, lactate dehydrogenase A; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; OAA, oxaloacetate; ACL, ATP citrate lyase; ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; FA, fatty acids; TCA, tricarboxylic acid; OXPHOS, oxidative phosphorylation.
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hepatoma cells (Moon et al., 1999) . In a recent report, the role of Sp in coordinating proliferation and lipogenesis in the context of cancer was investigated. In this work, the authors showed that Sp1 regulates both proliferation and FAS expression in human MCF-7 breast, HCT116 colon and LNCaP prostate cancer cells (Lu and Archer, 2009 ). Stimulation of proliferation by Sp1 is mediated by the regulation of specific cell-cycle proteins, such as CDC25A. This dual regulation of metabolic and proliferative genes by a single transcription factor supports the hypothesis that common regulatory pathways exist between proliferative and metabolic factors.
Carbohydrate responsive element-binding protein
One of the important advantages of aerobic glycolysis common regulatory pathways relies on the possibility to redirect glucose carbon flux into anabolic pathways such as de novo lipogenesis and nucleotide biosynthesis. Sensing increased glucose input is therefore of utmost importance for cancer cells to trigger an adequate transcriptional response. This relies, at least partially on the carbohydrate responsive element-binding protein (ChREBP), which is a glucose-responsive transcription factor. The critical role of ChREBP in mediating glucose-dependent induction of glycolytic and lipogenic genes has been extensively explored in nonproliferating hepatocytes (Yamashita et al., 2001; Dentin et al., 2004; Denechaud et al., 2008) . More recently, a role for ChREBP in proliferating cells has been described, showing its contribution in cancer cell proliferation and tumorigenesis through attenuation of p53 activity (Tong et al., 2009) . One important finding in this study is the demonstration that ChREBP suppression in HCT116 colorectal and HepG2 hepatic human cancer cell lines resulted in decreased glycolysis, associated with diminished de novo lipogenesis and nucleotide biosynthesis, although mitochondrial respiration was increased. These data strongly suggest the participation of ChREBP in the metabolic switch from OXPHOS to aerobic glycolysis in cancer cells, a hypothesis that will require further investigation.
Oncogenic pathways: from Akt to c-Myc and Ras
The serine/threonine kinase Akt (or PKB) is a paradigm of the dual and integrative regulation of metabolism and proliferation. Possibly, it is the most versatile factor that controls the metabolic response to both metabolic and oncogenic stimuli, such as insulin and Ras signaling. The function of Akt in metabolism covers from glucose homeostasis to protein and FA synthesis. It is also a component of the growth factor signaling transduction cascade regulating a wide range of cellular functions including growth, survival and proliferation (reviewed in Manning and Cantley, 2007) . Because Akt is known to be a major mediator of glucose uptake and use, it is thereby not surprising that Akt activity is correlated with high glycolytic rates in cancer cells (Elstrom et al., 2004) . Several studies have brought important clues to understand the participation of Akt in the glycolytic cancer phenotype. Indeed, growth-factor-induced Akt activation was shown to result in increased expression and membrane distribution of the GLUT1 glucose transporter (Barthel et al., 1999; Wieman et al., 2007; Wofford et al., 2008) , association of hexokinase I and II to the mitochondria (Gottlob et al., 2001; Majewski et al., 2004; Robey and Hay, 2006) and stimulation of phospho-fructokinase activity, thereby increasing glycolysis. In addition to its well-documented function in regulating glucose homeostasis, and cell proliferation, there is also growing evidence that Akt is important in activating de novo FA synthesis. Activation of Akt was shown to induce gene expression of numerous enzymes involved either in cholesterol or FA biosynthesis, including, but not limited to, the HMG-CoA synthase, HMG-CoA reductase, ACL, FAS and stearoyl-CoA desaturase (Porstmann et al., 2005) . Transcription of these enzymes regarding Akt pathway has been shown Dual role for the E2F pathway in the control of both cell proliferation and the metabolic response. In response to proliferative stimuli such as insulin, glucose and nutrients, the cyclincdk4 complex is activated and phosphorylates the retinoblastoma protein pRB, which represses transcription when associated with E2F transcription factors. Activated E2F1 stimulates the expression of target genes implicated in cell-cycle progression (blue circle). In addition, E2F1 triggers an adapted metabolic transcriptional response, depending on the cell type. In b-cells, E2F1 will stimulate the expression of Kir6.2, thus facilitating insulin secretion. In other cell types, such as muscle or cancer cells, E2F1 facilitates glycolysis and represses, by still unknown mechanisms, OXPHOS. This coordinated response is essential to sustain normal proliferation and development. It is conceivable that changes in this coordinated response might lead to abnormal metabolic changes during tumor development and cancer progression. TCA, tricarboxylic acid; OXPHOS, oxidative phosphorylation; OAA, oxaloacetate.
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to require the activity of the sterol-regulatory elementbinding protein (SREBP) family of transcription factors, of which synthesis and nuclear accumulation are also induced by activated Akt (Porstmann et al., 2005) . Of particular importance is the observation that Akt also directly phosphorylates and activates the ACL (Berwick et al., 2002; Bauer et al., 2005; Buzzai et al., 2005) , which is a key enzyme integrating glucose and lipid metabolism. Akt participates therefore in the first committed step in channeling glucose-derived metabolites toward a lipid biosynthetic fate. Myc or Ras oncogenes can be also considered as coordinators of the proliferative and metabolic response of transformed cells (DeBerardinis et al., 2008) . Altered expression or mutations in the Myc or Ras oncogenes have been associated to the genesis of most common human cancers. Apart from its role in the regulation of cell proliferation and cell cycle, there is compelling evidence that c-Myc and Ras also participate to the control of cancer cell metabolism. Because the discovery that c-Myc regulates the lactate dehydrogenase (LDH)-A (Shim et al., 1997; Lewis et al., 2000) , which converts pyruvate to lactate and contributes to the Warburg effect, c-Myc has been found to regulate directly many enzymes from the glycolytic pathway, therefore promoting glucose uptake and use (Osthus et al., 2000; Kim et al., 2004 Kim et al., , 2007 . Furthermore, many studies have evidenced that c-Myc also has a pivotal role in regulating mitochondrial biogenesis and function. This was supported by the observations that many genes involved in mitochondrial biogenesis and function are overexpressed among c-Myc direct transcriptional targets (Li et al., 2005; Kim et al., 2008; Morrish et al., 2008) . As one important issue discussed in this review is the participation of cell-cycle regulators in the metabolic control of cancer cells, it is worth mentioning the link between c-Myc and E2F1 pathway. Both c-Myc and E2F1 are important regulators of cell cycle, and it has been suggested that c-Myc metabolic gene targets are regulated in a cell-cycle-dependent way. Indeed, after induction of energy metabolism-and ribosomal biogenesis-related genes during the G 1 phase, c-Myc induces E2F1 expression as cells enter into the S phase, that together with c-Myc activates genes involved in nucleotides biosynthesis and DNA replication (Liu et al., 2008) . There is no need to discuss the importance of Ras oncogenes in the control of cell proliferation and tumor development (Drosten et al., 2010) . Interestingly, Rasmediated cell transformation is coupled to profound changes in metabolism, including enhanced glucose uptake and glycolysis, mitochondrial dysfunction and increased lactic acid production. This is the result of increased expression of several genes of the aerobic glycolytic pathway and LDH (Mazurek et al., 2001; Ramanathan et al., 2005; Chiaradonna et al., 2006) . Similar to other oncogenes, Ras also participates in the control of de novo lipid synthesis, mainly through regulation of the activity of the transcription factors SREBPs mediated by the mitogen-activated protein kinase pathway (Yang et al., 2002; Menendez et al., 2005) . Most interestingly, recent data from our lab show that Ras transformation is abrogated when lipid synthesis pathways are inhibited (Fritz et al., 2010) . Taken together, the available literature suggests that oncogenes are at the origin of the metabolic transformations observed during cell transformation. These metabolic changes contribute to sustained proliferation of cancer cells, creating a positive feedback loop. This is supported by the observation that changes in metabolism are also required to sustain the activation of oncogenes. Notably, oncogene-induced FA synthesis, such as described above, facilitates the formation of a subset of FA, such as palmitate and palmitoleate, which influence the traffic and cellular localization of several oncogenes, such as Ras, facilitating their anchorage to membranes required for the activation of their oncogenic pathways (Nadolski and Linder, 2007) . From these findings we can argue that inhibition of key enzymes involved in lipid synthesis will abrogate activation of oncogenic signaling, and therefore will result in tumor growth arrest. This has been shown for ACL , FAS (Kuhajda et al., 1994; Kuhajda, 2000) or stearoyl-CoA desaturase 1 (Scaglia and Igal 2008; Fritz et al., 2010) inhibition.
Counteracting tumor suppressor pathway
It is not surprising that tumor suppressors not only have opposite effects than oncogenes on the control of cell proliferation and cell cycle, but they also directly participate in the reversal of the glycolytic phenotype of the cells. Several examples are illustrative of this striking observation. The tumor suppressor p53, in addition to its well-known function in the control of cell cycle and apoptosis, is important in the control of glycolytic and oxidative metabolism. It was shown that p53 participates in mitochondrial biogenesis and function, oxygen consumption and decrease in glycolysis (Matoba et al., 2006) . These effects were mediated, at least in part, through direct transcriptional regulation of the synthesis of cytochrome c oxidase 2, and apoptosisinducing factor, which are essential genes in the control of mitochondrial function (Matoba et al., 2006) . Furthermore, opposite to oncogenes, such as Ras or Akt, p53 represses the expression of glucose transporters GLUT-1 and GLUT-4, thereby inhibiting glycolysis (Schwartzenberg-Bar-Yoseph et al., 2004) . In addition, p53 also senses the metabolic stress of the cell. Interestingly, under hypoxia or nutrient depletion, which are conditions characteristic of cancer cell environment, p53 appears to inhibit autophagy, which is required, under these conditions, to facilitate cancer cell growth (Tasdemir et al., 2008) . Phosphatase and tensin homologue (PTEN) is another major tumor suppressor. Most of its effects are mediated through inactivation of the PI3K/Akt pathway. It is indeed a phosphatase of phosphatidyl inositol triphosphate, which is a major effector of Akt. Loss-of-function mutations in PTEN are not only related to cancer development, but also show dramatic consequences for metabolism homeostasis. For instance, Pten-deleted muscle, liver or fat tissue shows increased glucose sensitivity indicating that PTEN modulates glucose uptake and use in the cells (Li et al., 1997; Stiles et al., 2004; Wijesekara et al., 2005) . This is of particular relevance in cancer cells, which are fully dependent on increased glycolytic flux. PTEN is also a negative regulator of the insulin pathway, and therefore has negative effects on lipogenesis, another hallmark of cancer cells. Paradoxically pRB is, in contrast to the other tumor suppressors, a major modulator of oxidative metabolism. RB-specific deletion in adipose tissue results in increased mitochondrial activity and reversal from anabolic white adipose tissue to catabolic oxidative brown adipose tissue (Dali-Youcef et al., 2007) . In this particular situation RB would facilitate a cancer-type metabolism. More studies are required, however, to better understand the role of pRB in the metabolic control in cancer cells.
Concluding remarks
It is well established that the process of cancer development and growth involves major alterations of cells' metabolism. In addition to triggering signaling cascades involved in proliferation and survival, oncogenes such as Ras, c-Myc or Akt, and most importantly cell-cycle regulators, such as the cdk4-E2F1 axis, also trigger concomitant metabolic changes. The majority of oncoproteins have been shown to stimulate aerobic glycolysis in transformed cells, including Akt, c-Myc, Ras and Src. Moreover, there is compelling evidence that in addition to trigger proliferation, oncogenes require the modification of metabolism, notably the increase in de novo FA synthesis to transform the cell. This modification in lipid synthesis results, in addition to other effects, in the activation of oncoproteins through protein lipidation. This creates a positive feedback loop that contributes to sustained cancer cell growth and proliferation.
Most efforts have been directed toward the inhibition of the proliferative and invasive effects of oncogenes in cancer cells, whereas little attention has been paid to the metabolic changes in these cells. Further identification of the particular metabolic pathways regulated by oncogenic factors will certainly contribute to broaden the therapeutic options for cancer treatment.
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